This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
by Zacks Equity Research
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
by Zacks Equity Research
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
by Zacks Equity Research
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.
Alexion's Ultomiris Receives EU Approval for PNH in Adults
by Zacks Equity Research
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.
Alexion Receives FDA Approval for Label Expansion of Soliris
by Zacks Equity Research
Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.
Alexion's sBLA for Ultomiris Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
by Zacks Equity Research
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
by Zacks Equity Research
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
by Zacks Equity Research
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) was a big mover last session, as the company saw its shares more than 9% on the day amid huge volumes.
Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%
by Zacks Equity Research
Alder BioPharmaceuticals, Inc. (ALDR) was a big mover last session, as the company saw its shares more than 15% on the day amid huge volumes.
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1%
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
Penumbra (PEN) Forms JV on Virtual Reality in Health Space
by Zacks Equity Research
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9%
by Zacks Equity Research
Audentes Therapeutics, Inc. (BOLD) was a big mover last session, as the company saw its shares nearly 15% on the day amid huge volumes.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
Anika Therapeutics Receives FDA Nod for Bone Repair Therapy
by Zacks Equity Research
Anika Therapeutics' (ANIK) FDA approved HA-based injectable bone repair therapy provides a commercial edge to regenerative portfolio.
PetMed Rides on Solid Reorders & New Orders Amid Competition
by Zacks Equity Research
PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.
NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018
by Zacks Equity Research
NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.
Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session
by Zacks Equity Research
Array BioPharma (ARRY) shares rose nearly 10% in the last trading session, amid huge volumes.
Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
What Falling Estimates & Price Mean for Vascular Biogenics (VBLT)
by Zacks Equity Research
Vascular Biogenics (VBLT) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) was a big mover last session, as the company saw its shares nearly 13% on the day amid huge volumes.